|
|
Exchange: |
Nasdaq National Market |
Security
Type: |
Common |
Shares
Out: |
11,270,000 |
Market
Cap: |
289.19(M) |
Last
Volume: |
197,427 |
Avg
Vol: |
196,881 |
52
Week Range: |
$13.82 - $26.5 |
|
Level
I Sector: |
Health Care |
Level
II Sector: |
Drugs |
Level
III Sector: |
Biotechnology |
|
Member Indexes:
|
NASDAQ BIOTECHNOLOGY |
|
NASDAQ COMPOSITE |
|
NASDAQ NNM COMPOSITE |
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : - |
Insider 3/6 Months : - |
|
Guru Rank Number : - |
Guru Rank Value : - |
Guru Occurances : - |
|
|
|
|
|
|
|
Company Profile XOMA is a biotech royalty aggregator. Co. has a portfolio of economic rights to milestone and royalty payments associated with partnered pre-commercial therapeutic candidates. Co.'s portfolio was built through licensing its proprietary products and platforms from its discovery and development business, combined with acquisitions of rights to milestones and royalties.
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
0 |
0 |
11,100 |
117,800 |
Total Buy Value |
$0 |
$0 |
$194,963 |
$2,088,813 |
Total People Bought |
0 |
0 |
2 |
3 |
Total Buy Transactions |
0 |
0 |
11 |
21 |
Total Shares Sold |
0 |
0 |
0 |
27,000 |
Total Sell Value |
$0 |
$0 |
$0 |
$809,425 |
Total People Sold |
0 |
0 |
0 |
2 |
Total Sell Transactions |
0 |
0 |
0 |
2 |
End Date |
2024-02-15 |
2023-11-14 |
2023-05-16 |
2022-05-16 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Varian John |
CEO |
|
2014-10-15 |
4 |
AS |
$3.87 |
$38,690 |
D/D |
(10,000) |
325,364 |
|
- |
|
Varian John |
CEO |
|
2014-10-15 |
4 |
OE |
$1.24 |
$12,400 |
D/D |
10,000 |
335,364 |
|
- |
|
Scannon Patrick J Md Phd |
Exec. VP & CSO |
|
2014-10-01 |
4 |
AS |
$4.09 |
$20,447 |
D/D |
(5,000) |
81,939 |
|
- |
|
Neal James R |
VP Business Development |
|
2014-09-30 |
5 |
A |
$4.00 |
$2,588 |
D/D |
647 |
147,327 |
|
- |
|
Rubin Paul D |
Sr. VP Clinical Dev. & CMO |
|
2014-09-30 |
5 |
A |
$4.00 |
$2,052 |
D/D |
513 |
76,895 |
|
- |
|
Rubin Paul D |
Sr. VP Clinical Dev. & CMO |
|
2014-09-15 |
4 |
AS |
$4.59 |
$22,939 |
D/D |
(5,000) |
72,021 |
|
- |
|
Rubin Paul D |
Sr. VP Clinical Dev. & CMO |
|
2014-09-15 |
4 |
OE |
$3.04 |
$15,200 |
D/D |
5,000 |
77,021 |
|
- |
|
Varian John |
CEO |
|
2014-09-15 |
4 |
AS |
$4.56 |
$45,577 |
D/D |
(10,000) |
325,364 |
|
- |
|
Varian John |
CEO |
|
2014-09-15 |
4 |
OE |
$1.24 |
$12,400 |
D/D |
10,000 |
335,364 |
|
- |
|
Walbert Timothy P |
Director |
|
2014-09-12 |
4 |
A |
$0.00 |
$0 |
D/D |
5,500 |
31,297 |
|
- |
|
Baker Julian |
Director |
|
2014-09-12 |
4 |
A |
$0.00 |
$0 |
I/I |
16,500 |
524,349 |
|
- |
|
Wyszomierski Jack L |
Director |
|
2014-09-12 |
4 |
A |
$0.00 |
$0 |
D/D |
5,500 |
31,297 |
|
- |
|
Van Ness W Denman |
Director |
|
2014-09-12 |
4 |
A |
$0.00 |
$0 |
D/D |
5,500 |
38,152 |
|
- |
|
Limber Joseph M |
Director |
|
2014-09-12 |
4 |
A |
$0.00 |
$0 |
D/D |
5,500 |
22,300 |
|
- |
|
Bowes William K Jr |
Director |
|
2014-09-12 |
4 |
A |
$0.00 |
$0 |
D/D |
5,500 |
32,368 |
|
- |
|
Rubin Paul D |
Sr. VP Clinical Dev. & CMO |
|
2014-09-04 |
4 |
AS |
$4.56 |
$45,640 |
D/D |
(10,000) |
72,021 |
|
- |
|
Rubin Paul D |
Sr. VP Clinical Dev. & CMO |
|
2014-09-04 |
4 |
OE |
$3.04 |
$30,400 |
D/D |
10,000 |
82,021 |
|
- |
|
Scannon Patrick J Md Phd |
Exec. VP & CSO |
|
2014-09-02 |
4 |
AS |
$4.31 |
$21,553 |
D/D |
(5,000) |
86,939 |
|
- |
|
Rubin Paul D |
Sr. VP Clinical Dev. & CMO |
|
2014-08-18 |
4 |
AS |
$4.36 |
$71,752 |
D/D |
(16,449) |
72,021 |
|
- |
|
Rubin Paul D |
Sr. VP Clinical Dev. & CMO |
|
2014-08-15 |
4 |
AS |
$4.31 |
$44,341 |
D/D |
(10,299) |
88,470 |
|
- |
|
Kurland Fred |
CFO & VP Finance |
|
2014-08-15 |
4 |
S |
$4.31 |
$44,780 |
D/D |
(10,401) |
71,263 |
|
- |
|
Neal James R |
VP Business Development |
|
2014-08-15 |
4 |
S |
$4.61 |
$30,322 |
D/D |
(6,584) |
144,857 |
|
- |
|
Varian John |
CEO |
|
2014-08-15 |
4 |
AS |
$4.30 |
$279,035 |
D/D |
(64,823) |
325,364 |
|
- |
|
Varian John |
CEO |
|
2014-08-15 |
4 |
OE |
$1.24 |
$12,400 |
D/D |
10,000 |
335,364 |
|
- |
|
Scannon Patrick J Md Phd |
Exec. VP & CSO |
|
2014-08-15 |
4 |
S |
$4.31 |
$25,277 |
D/D |
(5,871) |
91,939 |
|
- |
|
594 Records found
|
|
Page 13 of 24 |
|
|